![]() | Up a level |
Humby, Frances, Durez, Patrick, Buch, Maya H, Lewis, Myles J, Rizvi, Hasan, Rivellese, Felice, Nerviani, Alessandra, Giorli, Giovanni, Mahto, Arti, Montecucco, Carlomaurizio et al (show 20 more authors)
(2021)
Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis (R4RA): 16-week outcomes of a stratified, biopsy-driven, multicentre, open-label, phase 4 randomised controlled trial.
LANCET, 397 (10271).
pp. 305-317.
Rivellese, Felice ORCID: 0000-0002-6759-7521, Surace, Anna EA
ORCID: 0000-0001-9589-3005, Goldmann, Katriona
ORCID: 0000-0002-9073-6323, Sciacca, Elisabetta
ORCID: 0000-0001-7525-1558, Çubuk, Cankut
ORCID: 0000-0003-4646-0849, Giorli, Giovanni, John, Christopher R, Nerviani, Alessandra
ORCID: 0000-0003-4064-4014, Fossati-Jimack, Liliane
ORCID: 0000-0003-3757-3999, Thorborn, Georgina et al (show 12 more authors)
(2022)
Rituximab versus tocilizumab in rheumatoid arthritis: synovial biopsy-based biomarker analysis of the phase 4 R4RA randomized trial.
Nature medicine, 28 (6).
pp. 1256-1268.